Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 5/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30868578 | 1.00 | LMNA (0.48) | LMNASMN1; SMN2PKMPIK3CDPIK3R1 | |
| SCHEMBL30868583 | 0.93 | LMNA (0.42) | LMNASMN1; SMN2PKMMAPK1ABL1 | |
| SCHEMBL24631405 | 0.93 | LMNA (0.42) | LMNASMN1; SMN2PKMMAPK1ABL1 | |
| SCHEMBL30868613 | 0.83 | KIF11 (0.45) | PKMALDH1A1 | |
| SCHEMBL24631163 | 0.83 | KIF11 (0.45) | PKMALDH1A1 | |
| SCHEMBL24631196 | 0.83 | BRD4 (0.38) | LMNASMN1; SMN2PKMMAPK1ABL1 | |
| SCHEMBL30868556 | 0.83 | BRD4 (0.38) | LMNASMN1; SMN2PKMMAPK1ABL1 | |
| SCHEMBL24631240 | 0.83 | MAPT (0.44) | LMNASMN1; SMN2PKMMAPK1ABL1 | |
| SCHEMBL24631171 | 0.77 | BRAF (0.45) | LMNASMN1; SMN2PKMMAPK1KMT2A | |
| SCHEMBL30868535 | 0.77 | BRAF (0.45) | LMNASMN1; SMN2PKMMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083903-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | MERCK SHARP & DOHME LLC (US) | 2024-03-14 | — | — | US | disclosed |
| WO-2022177869-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | MERCK SHARP & DOHME LLC (US) | 2022-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083903-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | TEAD2, TEAD3, TEAD4 | LMNA 4282/4885SMN1; SMN2 3936/4885PKM 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.